Although there were no differences in CD8+ T cells between tumor and normal tissues, we found that CD8+ T cells were associated with better prognosis in advanced stage NSCLC patients, which was consistent with previous studies (5, 13). This evidence concerns the gene CD8A and non-small cell lung carcinoma.